Medicine:Sinopharm CNBG COVID-19 vaccine
From HandWiki
Short description: Vaccine against COVID-19
| Vaccine description | |
|---|---|
| Target disease | SARS-CoV-2 |
| Type | Protein subunit |
| Clinical data | |
| Routes of administration | Intramuscular |
| Legal status | |
| Legal status |
|
Sinopharm NVSI COVID-19 vaccine, also known as mutI-tri-RBD or NVSI-06-08, is a COVID-19 vaccine developed by National Vaccine & Serum Institute (NVSI, 中生研究院), a subsidiary of CNBG of Sinopharm.[1][2]
They claim to be the world's first "second generation broadly protective" recombination protein subunit vaccine, i.e. by combining three heterogeneous antigens into one single trimer RBD protein (突变集成三聚化RBD, mutI-tri-RBD).[3] It's based on the original, and the Beta (K417N/E484K/N501Y) and Kappa (L452R/E484K) variants.[4]
References
- ↑ "Emergency use of Sinopharm's new CNBG protein vaccine approved in UAE". Gulf News. 27 December 2021. https://gulfnews.com/uae/emergency-use-of-sinopharms-new-cnbg-protein-vaccine-approved-in-uae-1.84628476.
- ↑ Script error: No such module "cite news".
- ↑ 國藥集團：二代重組蛋白新冠疫苗保護效果良好
- ↑ "Safety and immunogenicity of a hybrid-type vaccine booster in BBIBP-CorV recipients in a randomized phase 2 trial". Nature Communications 13 (1): 3654. June 2022. doi:10.1038/s41467-022-31379-0. PMID 35760812. Bibcode: 2022NatCo..13.3654K.
 |
